Focal Pulsed Field Ablation of Ventricular Tachycardia
NCT07929545, Enrolling by invitation, Sana Hanse Hospital Wismar
Trial 8
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Focal Pulsed Field Ablation of Ventricular Tachycardia | ClinicalTrials.gov |
| NCT number | NCT07929545 | ClinicalTrials.gov |
| Status | Enrolling by invitation | ClinicalTrials.gov |
| Enrollment | 100 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Sana Hanse Hospital Wismar | ClinicalTrials.gov |
| Conditions | Ventricular Tachycardia (VT), Structural Heart Disease, Ischemic Cardiomyopathy, Hypertrophic Cardiomyopathy (HCM), Dilated Cardiomyopathy (DCM), Arrhythmogenic Cardiomyopathy (AC, ARVD/C), Electrical Storm | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Freedom From Ventricular Tachycardia Recurrence After Focal PFA VT Ablation | From index ablation with the Centauri™ PFA System procedure to 12 months of follow-up. | Proportion of patients free from recurrent ventricular tachycardia after clinically indicated VT ablation using the Centauri™ PFA System. VT recurrence is defined as documented sustained VT, appropriate ICD therapy including antitachycardia pacing or shock, arrhythmia-related hospitalization, or repeat VT ablation during follow-up. | ClinicalTrials.gov |
| Secondary | Incidence of Acute Procedure-Related Adverse Events | Periprocedural | Proportion of patients experiencing acute procedure-related adverse events during or immediately after clinically indicated VT ablation using the Centauri™ PFA System. Events include pericardial effusion or tamponade, vascular complications, coronary spasm or coronary injury, conduction disturbances, stroke or transient ischemic attack, myocardial infarction, acute heart failure deterioration, sustained hemodynamic instability, procedure-related death, or other clinically relevant complications. | ClinicalTrials.gov |
| Secondary | Acute Procedural Success of Focal PFA VT Ablation | During the index ablation procedure; assessed at the end of the procedure. | Proportion of patients achieving acute procedural success after clinically indicated ventricular tachycardia ablation using the Centauri™ PFA System. Acute procedural success is defined as non-inducibility of the targeted clinical VT or relevant sustained monomorphic VT at the end of the procedure, and/or abolition of targeted arrhythmogenic substrate or local abnormal ventricular electrograms according to the predefined procedural strategy. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)